Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis  by Ni, Wentao et al.
b r a z j i n f e c t d i s . 2 0 1 5;1  9(2):170–180
w w w.  elsev ier .com/ locate /b j id
The Brazilian Journal of
INFECTIOUS  DISEASES
Original article
Efﬁcacy  of  polymyxins  in  the treatment  of
carbapenem-resistant Enterobacteriaceae  infections:
a systematic  review  and  meta-analysis
Wentao Nia, Xuejiu Caia, Chuanqi Weia, Xiuzhen Dib, Junchang Cuia,∗,
Rui  Wangb, Youning Liua
a Department of Respiratory Diseases, Chinese People’s Liberation Army General Hospital, Beijing, China
b Department of Clinical Pharmacology, Chinese People’s Liberation Army General Hospital, Beijing, China
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 1 October 2014
Accepted 13 December 2014
Available online 28 January 2015
Keywords:
Polymyxin
Enterobacteriaceae
Carbapenem-resistant
Carbapenemase-producing
a  b  s  t  r  a  c  t
In recent years, carbapenem-resistant Enterobacteriaceae has become endemic in many
countries. Because of limited treatment options, the abandoned “old antibiotics”, polymyx-
ins,  have been reintroduced to the clinic. To evaluate the clinical efﬁcacy of polymyxins
in  the treatment of infections caused by carbapenem-resistant Enterobacteriaceae, we  sys-
temically searched the PubMed, Embase, and Cochrane Library databases and analyzed the
available evidence. The Preferred Reporting Items for Systematic reviews and Meta-Analysis
statement were followed, and the I2 method was used for heterogeneity. Nineteen controlled
and  six single-arm cohort studies comprising 1086 patients met the inclusion criteria. For
controlled studies, no signiﬁcant difference was noted for overall mortality (OR, 0.79; 95% CI,
0.58–1.08; p = 0.15), clinical response rate (OR, 1.24; 95% CI, 0.61–2.54; p = 0.55), or microbiolog-
ical  response rate (OR, 0.59; 95% CI, 0.26–1.36; p = 0.22) between polymyxin-treated groups
and  the control groups. Subgroup analyses showed that 28-day or 30-day mortality was
lower in patients who received polymyxin combination therapy than in those who received
monotherapy (OR, 0.36; 95% CI, 0.19–0.68; p < 0.01) and the control groups (OR, 0.49; 95% CI,
0.31–0.75; p < 0.01). The results of the six single-arm studies were in accordance with the
ﬁndings of controlled studies. One controlled and two single-arm studies that evaluated the
occurrence of nephrotoxicity reported a pooled incidence rate of 19.2%. Our results suggest
that polymyxins may be as efﬁcacious as other antimicrobial therapies for the treatment
of  carbapenem-resistant Enterobacteriaceae infection. Compared to polymyxin monotherapy,
combination regimens may achieve lower 28-day or 30-day mortality. Future large-volume,well-designed randomize
in treating carbapenem-re
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1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.d control trials are required to determine the role of polymyxins
sistant Enterobacteriaceae infections.
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method) models were used according to the heterogene-b r a z j i n f e c t d i s .
ntroduction
n recent years, carbapenemase-producing Enterobacteriaceae,
he majority of which is carbapenem-resistant (CRE), have
osed a great threat to public health.1 Outbreaks and
ncreased prevalence due to these notorious superbugs have
een continuously reported in hospitals worldwide, resulting
n high mortality.2 Production of Klebsiella pneumoniae car-
apenemase (KPC) enzymes is the most common mechanism
f resistance, while the incidence of zinc-dependent metallo-
-lactamases (VIM, IMP, and NDM types) is also increasing.3
he carbapenemase-producing strains can exhibit resistance
o most clinically available -lactams, as well as other
mportant antimicrobial classes such as aminoglycosides
nd ﬂuoroquinolones.4 Multidrug-resistant (MDR) Enterobacte-
iaceae make the empiric choice of appropriate antimicrobial
reatment very difﬁcult; moreover, the best approach for treat-
ng CRE infections is not currently known.
Polymyxins, a group of polypeptide antibiotics, demon-
trate potent antimicrobial activity against MDR  Gram-
egative bacteria by disrupting the outer membrane.5 They
ere abandoned in the 1960s because of severe adverse
ffects5; however, limited options for treating infections
aused by MDR  Gram-negative bacteria have forced clinicians
o reuse old drugs.6 So far, many  clinical studies have eval-
ated the efﬁcacy of polymyxins in the treatment of CRE
nfections, yielding various results. Furthermore, the signif-
cant pharmacokinetic deﬁciencies of polymyxins and the
apid emergence of resistance during treatment have led
any clinicians to embrace combination regimens as the pre-
erred treatment strategy for CRE infections.7 Nonetheless, the
mportant question on whether combination therapy, which
ay increase toxicity and cost, can bring more  beneﬁt than
onotherapy remains unanswered.
Therefore, in this study, we systemically searched and ana-
yzed the available evidence in order to evaluate the efﬁcacy
f polymyxins in the treatment of infections caused by CRE,
nd to examine whether polymyxin combination therapy can
ffer an advantage over monotherapy.
ethods
earch  strategies
e  searched the PubMed, Embase, and Cochrane Library
atabases from their inception until August 30, 2014 using the
ollowing search terms: (CRE or carbapenem-resistant or KPC
r carbapenemase-producing or VIM or NDM or OXA or IMP)
nd (Escherichia or Klebsiella or Enterobacter or Proteus or Serratia
r Citrobacter or Salmonella or Shigella or Enterobacteriaceae)  and
colistin or polymyxin). The references listed in the identiﬁed
tudies were also searched to select relevant articles. No lan-
uage restrictions were applied. The Preferred Reporting Items
or Systematic reviews and Meta-Analysis (PRISMA) statement
ere used in the identiﬁed articles. Two investigators (Ni and
ai) independently performed the literature search and study
election. A third author (Wei) resolved any disagreements,
nd a ﬁnal consensus was reached among all authors.5;1 9(2):170–180 171
Selection  criteria
Studies were considered eligible for inclusion if they provided
clinical outcomes of polymyxin therapy for infections caused
by carbapenemase-producing Enterobacteriaceae or CRE. For
studies reporting the outcomes of both colonized and infected
patients, only those of infected patients were extracted.
Experimental trials in animals, trials focusing on pharmacoki-
netic or pharmacodynamic (PK/PD) variables, trials referring
only to the in vitro activity of polymyxins, and incomplete
unpublished studies were excluded. Case reports and case-
series including fewer than 10 infected patients were also
excluded.
Ethical  considerations
This study did not require the approval of an ethics committee.
Data  extraction  and  quality  assessment
The following variables were collected from the included
studies by two independent reviewers: author, publication
year, country, study design, main characteristics and sever-
ity of illness (APACHE scores) of the study population,
causative pathogens, antibiotic susceptibility testing meth-
ods and breakpoints, sites of infections, type and dose of
polymyxin administered, coadministration of other antibi-
otics, outcomes (clinical response, microbiologic eradication,
and mortality), and reported toxicity (nephrotoxicity and neu-
rotoxicity).
The quality of the included studies was assessed using
the modiﬁed Newcastle-Ottawa scale (NOS), which consists
of three factors: patient selection, comparability of the study
groups, and outcome assessment.8 Studies with a NOS score
<3 were classiﬁed as having poor quality and were excluded
from this systematic review.
Deﬁnitions  and  statistical  analysis
Because patients with CRE infections show high mortal-
ity rates, we chose mortality as the primary outcome. The
secondary outcomes were clinical response, microbiologic
eradication, and incidence of toxicity. Because of the lack
of standard and uniform criteria for assessing and repor-
ting these secondary outcomes, we accepted the criteria as
reported in each study.
All statistical analyses were performed with the Com-
prehensive Meta-Analysis V2.2 (Biostat, Englewood NJ).
The between-study heterogeneity was assessed by using
2-based Q statistics and the I2 test. Heterogeneity was con-
sidered as I2 > 50%. Either ﬁxed effects (Mantel–Haenszel
method) or random effects (DerSimonian and Laird’sity result. Binary outcomes results of controlled studies
were expressed as odds ratios (ORs). Egger regression
and Begg and Mazumdar methods were used to evaluate
publication bias, and p < 0.05 was considered statistically
signiﬁcant.
i s . 2 0172  b r a z j i n f e c t d 
Results
A total of 1189 potentially relevant references were initially
identiﬁed by searching the PubMed, Embase, and Cochrane
Library databases (Fig. 1). Titles and abstracts were reviewed to
exclude irrelevant studies. Two-hundred and thirty-two arti-
cles with full texts were screened, and 25 studies met  the
inclusion criteria.9–33 The examination of the references of
these included studies and review articles did not yield any
further studies for evaluation. The NOS score of all included
studies was >3.
Study  characteristics
The characteristics of the included studies are presented
in Table 1 . Among the 25 included studies, six involving
175 patients were single-arm studies, and 19 involving 911
patients were controlled studies. Two out of six single-arm
studies were prospective studies, and the others were ret-
rospective studies. Eight out of 19 controlled studies were
prospective studies, and 11 were retrospective studies. Most
patients in the included studies were critically ill. Twenty-two
studies involving 881 patients reported that the proportion
of patients in the intensive care unit was 64.6%. The average
APACHE score of patients in 14 studies using this parameter
was >20. Nine studies reported on CRE infections, and 16 other
studies reported on carbapenemase-producing Enterobacte-
riaceae infections. Klebsiella spp. were the major causative
pathogen, and bacteremia was the most common manifes-
tation, followed by pneumonia and urinary tract infection.Mortality
Among the 19 controlled studies, 18 involving 824 patients
reported the mortality rate. As shown in Fig. 2, no
Pubmed: n=254 Embase: n=893 Coch
Du
Studies identified through
initial searches of electronic
databases: n=1189
Titles and abstracts
screened: n=946
Full-text articles screened:
n=232
Included studies:
n=25
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Fig. 1 – Flow chart of the art 1 5;1  9(2):170–180
signiﬁcant difference in overall mortality was noted when
the polymyxins-treated groups were compared with the con-
trol groups (OR, 0.79 [95% conﬁdence interval (CI), 0.58–1.08;
p = 0.15]; I2 = 0%; Q = 15.12 [p = 0.59]). The subgroup analysis of
controlled studies is presented in Table 2.
For the six single-arm studies, the pooled overall mor-
tality rate was 35.7% (95% CI, 0.22–0.53; I2 = 74.85%; Q = 19.88
[p = 0.001]), which was in line with the results of the con-
trolled studies (33.8% [95% CI, 0.29–0.39]; I2 = 27.43%; Q = 23.43
[p = 0.14]).
The subgroup analysis by mortality type is shown in
Table 3. With respect to 28-day or 30-day mortality, no sig-
niﬁcant difference was observed between the polymyxin
monotherapy and control groups, while signiﬁcantly lower
mortality was noted in the combination therapy group. For
other subgroup analyses, such as in-hospital mortality, 14-
day mortality, and all-cause mortality, the rate did not differ
signiﬁcantly between the polymyxin-treated groups and the
control groups. In addition, one study compared colistin
with other antibiotics in terms of infection-related mortal-
ity, and no signiﬁcant difference was found between the two
groups.
No publication bias was detected by using Egger regression
or Begg and Mazumdar rank correlation. Therefore, the funnel
plot for publication bias demonstrated no marked evidence of
asymmetry, as shown in Fig. 3.
Clinical  response
Four studies involving 153 patients compared the clinical
response of colistin-based therapy with that of other antibi-
otic regimens. As shown in Fig. 2, no signiﬁcant difference was
observed between the two groups (OR, 1.24 [95% CI, 0.61–2.54;
p = 0.55]; I2 = 47.45%; Q = 5.71 [p = 0.13]). For the single-arm
rane: n=42
plications: n=243
cluded studies: n=714
vitro or animal studies: n=65
elevant topics: n=649
xcluded studies: n=207
eviews or meeting abstracts: n=162
tudies not reporting clinical outcomes: n=9
tudies with unclear antibiotic treatment: n=13
ase reports and case-series including
wer than 10 infected patients: n=23
icles selection process.
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Table 1 – Characteristics of studies included in systematic review and meta-analysis.
Author (year) Country and
district
Type of study Population characteristics Polymyxin
group
Concomitant
antibiotics
administered
Daikos (2009)9 Greece Prospective, 2 arms Inpatients Colistin Carba
Michalopoulos (2010)10 Greece Prospective, 2 arms ICU patients; DM, COPD; Mean APACHE
score = 23.4 ± 4.9
Colistin  Fos
Nguyen (2010)11 United States Retrospective, 2 arms Inpatients (52.1% were ICU patients); Median
APACHE score = 19 (range 12–35)
Polymyxin B Tige
Souli (2010)12 Greece Retrospective, 2 arms Inpatients (64.7% were ICU patients); Mean
APACHE score = 18.9 ± 7.4
Colistin Carba, Tige, AG, FQ, Tzp
Satlin (2011)13 United States Retrospective, 2 arms 2 were outpatients; 85 were Inpatients (15%
were ICU patients)
Polymyxin B None
Zarkotou (2011)14 Greece Prospective, 2 arms Inpatients (71.7% were in the ICU patients);
Mean APACHE score = 21.1 ± 8.2
Colistin  Carba, Tige, AG
Alexander (2012)15 United States Retrospective, 2 arms Inpatients (21.4% were ICU patients) Colistin AG, Dox
Bergamasco (2012)16 Brazil Retrospective, 2 arms Solid-organ transplant recipients Polymyxin B Carba, Tige
Qureshi (2012)17 United States Retrospective, 2 arms Inpatients (52.9% were ICU patients at
enrollment); 51.2% had an APACHE score ≥20
Colistin; Polymyxin B Carba, Tige, FQ
Sanchez (2012)18 Spain Retrospective, 2 arms ICU patients; Mean APACHE
scores = 21.5 ± 5.8
Colistin Tige, AG
Tumbarello (2012)19 Italy Retrospective, 2 arms Inpatients (13.6% were in shock); Mean
APACHE score >30
Colistin Carba, Tige, AG
Capone (2013)20 Italy Prospective, 2 arms Inpatients (48.4% were ICU patients); Median
APACHE score = 15 (range 12–20)
Colistin  Tige, AG, Fos
Navarro (2013)21 Spain Prospective, 2 arms Inpatients (23.5% were ICU patients); septic
shock or severe sepsis (60%))
Colistin Carba, Tige, AG, Fos
Balkan (2014)22 Turkey Retrospective, 2 arms Inpatients (58.8% were ICU patients) Colistin Carba, Tige, AG
Daikos (2014)23 Greece Retrospective, 2 arms Inpatients (56.6% were ICU patients) Colistin Carba, Tige, AG
Huang (2014)24 Taiwan Retrospective, 2 arms Inpatients (60.5% were ICU patients) Colistin None
Kontopidou (2014)25 Greece Prospective, 2 arms ICU patients; Mean APACHE score ≥20 Colistin Carba, Tige, AG
Papadimitriou (2014)26 Greece Prospective, 2 arms ICU patients; Mean APACHE score = 16 ± 8.0 Colistin Tige, AG
Pontikis (2014)27 Greece Prospective, 2 arms ICU patients, Mean APACHE
scores = 18.13 ± 5.6
Colistin  Carba, Tige, AG, Tzp
Souli (2008)28 Greece Retrospective, single arm Inpatients (58.8% were ICU patients); Median
APACHE score = 22 (range 10–33)
Colistin  Carba, AG, Tzp, FQ, Dox
Maltezou (2009)29 Greece Retrospective, single arm ICU patients Colistin Tige, AG
Mouloudi (2010)30 Greece Retrospective, single arm ICU patients Colistin AG
Di Carlo (2013)31 Italy Prospective, single arm ICU patients, Mean APACHE scores = 23.4
±1.7
Colistin Tige
Dubrovskaya (2013)32 United States Retrospective, single arm Inpatients (52.5% were ICU patients) Colistin None
Crusio (2014)33 Netherlands Prospective, single arm Inpatients; Mean APACHE scores = 20 Polymyxin B Carba, A-S
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Table 1 – (Continued)
Author (year) Control
group
Sample  size
(Polymyxin
group/Control group)
Type of
infection
Organisms isolated Susceptibility testing method
(susceptibility breakpoints used)
Polymyxins Other antibiotics
Daikos (2009)9 Carba, AG 23/26 BSI VIM-1-producing Klebsiella
pneumoniae
Etest (CLSI, 2004) Etest (CLSI, 2004)
Michalopoulos (2010)10 Fos, AG, Tzp 6/5 BSI, VAP, UTI,
Wound
infection
Carbapenem-resistant K.
pneumoniae
NA  NA
Nguyen (2010)11 Tige, other 22/26 BSI Carbapenem-resistant K.
pneumoniae
Etest (CLSI, 2009) Etest; Vitek 2 automated
system (CLSI, 2009)
Souli (2010)12 Carba, Tige,
AG, Tzp
14/3 BSI, SSI, UTI,
HAP
KPC-producing K.
pneumoniae
Etest (EUCAST, 2009) Etest; Agar dilution (CLSI,
2009; FDA)
Satlin (2011)13 Tige, AG 25/62 UTI Carbapenem-resistant K.
pneumoniae
Etest (CLSI, 2011) Etest; Vitek 2 automated
system (CLSI, 2011; FDA)
Zarkotou (2011)14 Carba, Tige,
AG
21/14  BSI KPC-producing K.
pneumoniae
Broth microdilution
(EUCAST, 2010)
Vitek 2 automated system;
Broth microdilution (CLSI,
2010)
Alexander (2012)15 AG, Dox, FQ,
Ntf
2/12 UTI, BSI KPC-producing K.
pneumoniae
Disk  diffusion (CLSI, 2006) Disk diffusion; Etest (CLSI,
2006)
Bergamasco (2012)16 Carba, Tige 9/3 BSI, UTI, SSI,
HAP
KPC-producing K.
pneumoniae
Etest (CLSI, 2009) Disk diffusion; Etest (CLSI,
2009; FDA)
Qureshi (2012)17 Carba, Tige,
AG, FQ, Azt,
Cfpm, Tzp,
A-S
14/20  BSI KPC-producing K.
pneumoniae
Broth microdilution (CLSI,
2011)
Broth microdilution; Etest
(CLSI, 2011)
Sanchez (2012)18 Carba, Tige,
AG
12/12  Pneumonia,
LRTI, UTI,
Meningitis,
BSI, IAI, SSTI
VIM-1-producing K.
pneumoniae
Broth microdilution; Etest
(CLSI, 2011)
Broth microdilution; Etest
(CLSI, 2011; EUCAST, 2011)
Tumbarello (2012)19 Carba, Tige,
AG
61/36  BSI KPC-producing K.
pneumoniae
Vitek 2 automated system
(CLSI, 2011)
Vitek  2 automated system
(CLSI, 2011; FDA)
Capone (2013)20 Tige, AG, Fos 36/22 BSI, UTI,
Septic shock,
LRTI, SSTI
KPC-producing K.
pneumoniae
Broth microdilution
(EUCAST, 2010)
Broth microdilution
(EUCAST, 2010)
Navarro (2013)21 Carba, Tige,
AG, Fos, FQ,
Cef
18/16 BSI OXA-48-producing
Enterobacteriaceae (K.
pneumoniae, Escherichia coli)
Etest (CLSI, 2012) Vitek 2 automated system;
Etest (CLSI, 2012; FDA)
Balkan (2014)22 Carba, Tige,
AG
24/12  BSI OXA-48-producing
Enterobacteriaceae (K.
pneumoniae, E. coli,
Enterobacter aerogenes)
Etest (EUCAST, 2013) Etest (EUCAST, 2013)
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Daikos (2014)23 Carba, Tige,
AG, other
78/86 BSI Carbapenem-Resistant K.
pneumoniae
Etest (EUCAST, 2013) Etest; Vitek 2 automated
system (EUCAST, 2013)
Huang (2014)24 Carba, Tige 4/29 NA Carbapenem-resistant
Enterobacteriaceae (K.
pneumoniae, E. coli)
Broth  microdilution
(EUCAST, 2012)
Broth microdilution
(EUCAST, 2012)
Kontopidou (2014)25 Tige, AG, FQ 57/50 VAP, UTI, BSI,
SSI, IAI
Carbapenem-Resistant K.
pneumoniae
Vitek 2 automated system
(EUCAST, 2012)
Etest; Vitek 2 automated
system (CLSI, 2010;
EUCAST, 2012)
Papadimitriou (2014)26 Tige, AG 19/17 BSI KPC-producing K.
pneumoniae
Etest (CLSI, 2011) Etest, Disk diffusion (CLSI,
2011)
Pontikis (2014)27 Tige, AG 10/5 BSI, UTI, VAP,
IAI,
Meningitis
Carbapenem-Resistant K.
pneumoniae
Vitek 2 automated system
(CLSI, 2012)
Vitek 2 automated system
(CLSI, 2012; FDA)
Souli (2008)28 NA 16/NA BSI; VAP VIM-1, MBL producing
Enterobacteriaceae (Klebsiella
spp., Enterobacter spp.)
Etest  (BSAC) Disk; Etest (CLSI, 2006)
Maltezou (2009)29 NA 11/NA Pneumonia,
SSI
KPC-2-producing  K.
pneumoniae
Etest (CLSI, 2007) Disk; Etest (CLSI, 2007)
Mouloudi (2010)30 NA 53/NA BSI KPC, MBL producing K.
pneumoniae
Etest (EUCAST, 2010) Etest, Broth microdilution
(CLSI, 2007; FDA)
Di Carlo (2013)31 NA 30/NA SSI, IAI, KPC-producing K.
pneumoniae
Etest (EUCAST, 2013) Broth microdilution
(EUCAST, 2013)
Dubrovskaya (2013)32 NA 40/NA BSI, UTI, SSI,
Pneumonia,
IAI
Carbapenem-Resistant K.
pneumoniae
Etest (CLSI, 2012) Etest; Vitek 2 automated
system (CLSI, 2012; FDA)
Crusio (2014)33 NA 25/NA BSI, VAP, UTI Carbapenem-Resistant K.
pneumoniae
Vitek 2 automated system
(CLSI, 2009)
Vitek 2 automated system
(CLSI, 2009)
Abbreviation:  NA, not applicable; ICU, intensive care unit; BSI, bloodstream infection; VAP, ventilator-associated pneumonia; UTI, urinary tract infection; SSI, surgical-site infection; HAP, hospital-
acquired pneumonia; LRTI, lower respiratory tract infection; IAI, intra-abdominal infection; SSTI, skin and soft tissue infection. Carba, carbapenem; Tige, tigecycline; Ntf, nitroceﬁn; Fos, fosfomycin;
AG, aminoglycoside; A-S, ampicillin-sulbactam; Azt, aztreonam; FQ, ﬂuoroquinolone; Caz, ceftazidime; Cfpm, cefepime; Cef, Ceftriaxone; Tzp, piperacillin-tazobactam; Dox, doxycycline; CLSI, Clinical
and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; FDA, Food and Drug Administration; BSAC, British Society for Antimicrobial Chemotherapy.
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Daikos (2009)
Michalopoulos (2010)
Nguyen (2010)
Souli (2010)
Zarkotou (2011)
Alexander (2012)
Bergamasco (2012)
Navarro (2012)
Qureshi (2012)
Sanchez (2012)
Tumbarello (2012)
Capone (2013)
Balkan (2014)
Daikos (2014)
Huang (2014)
Kontopidou (2014)
Papadimitriou (2014)
Pontikis (2014)
Overall
Souli (2010)
Alexander (2012)
Kontopidou (2014)
Pontikis (2014)
Overall
Satlin (2011)
Alexander (2012)
Pontikis (2014)
Overall
Huang (2014)
Clinical response
Microbiological response
Study name Statistics for each study
Lower
limit
Upper
limit p-Value
Odds ratio and 95% CI
Relative
weight
Mortality
0.57
6.11
0.67
3.60
0.86
0.84
0.25
0.78
0.83
2.80
0.39
2.44
0.36
0.95
0.61
0.84
0.38
4.00
0.79
0.19
0.65
1.72
1.24
0.06
0.67
3.00
0.24
0.25
0.59
0.14
0.23
0.21
0.26
0.16
0.03
0.20
0.20
0.53
0.17
0.59
0.08
0.50
0.07
0.34
0.09
0.32
0.58
0.01
0.02
0.80
0.00
0.61
0.25
0.14
0.02
0.02
0.02
0.26
1.81
64.26
2.54
3.10
1.36
4.29
21.18
3.72
1.45
2.54
2.28
162.73
2.13
50.33
4.62
23.58
3.01
3.42
14.74
0.91
10.07
1.52
1.79
4.98
2.10
1.65
49.60
1.08
4.00
0.43
0.28
0.49
0.34
0.86
0.92
0.72
0.80
0.22
0.03
0.22
0.16
0.86
0.65
0.72
0.20
0.28
0.15
0.33
5.04
0.89
7.14
1.38
3.42
0.87
5.27
4.83
3.49
13.42
4.78
4.59
23.78
2.19
11.65
4.48
1.52
100.00
1.25
0.43
0.29
0.81
0.17
0.08
0.55
0.48
0.23
0.28
0.22
0.01 1 100
5.15
4.18
85.51
5.15
100.00
69.88
7.28
12.06
10.78
100.00
Odds
ratio
Fig. 2 – The efﬁcacy of polymyxins compared with other antibiotics in treating infections caused by
m-recarbapenemase-producing Enterobacteriaceae and carbapene
studies (three studies; 81 patients), the favorable clinical
response was 75% (95% CI, 0.64–0.83; I2 = 0%; Q = 1.50 [p = 0.47]).
One study compared colistin combination therapy (13 of
31 patients) with monotherapy (8 of 26 patients), and no
signiﬁcant difference was found between the two groups
(p = 0.55).
Microbiological  response
As shown in Fig. 2, four studies involving 149 patients
reported the outcome of microbiological response. No
signiﬁcant difference was noted between the polymyxin-
treated groups and the control groups (OR, 0.59 [95%
CI, 0.26–1.36; p = 0.22]; I2 = 0%; Q = 2.17 [p = 0.54]). In three
single-arm studies (62 patients), the overall microbiological
response rate was 51% (95% CI, 0.38–0.63; I2 = 28.30%; Q = 2.79
[p = 0.25]).sistant Enterobacteriaceae.
Adverse  events
Neurotoxicity was not reported in any of the studies. Only
one controlled study and two single-arm studies evaluated
the occurrence of nephrotoxicity. Pooled analysis showed an
incidence rate of 19.2% (95% CI, 0.08–0.39; I2 = 67.12%; Q = 6.08
[p = 0.05]).
Discussion
Carbapenemase-producing Enterobacteriaceae,  particularly
KPC-producing K. pneumoniae, is now widespread and
endemic in many  countries.34 Infections caused by these
MDR organisms are associated with high treatment failure
and mortality.35 However, available effective therapeutic
options are scarce. In this situation, polymyxins, which
exhibit potent in vitro activity against MDR  Gram-negative
b r a z j i n f e c t d i s . 2 0 1 5;1 9(2):170–180 177
Table 2 – Subgroup analysis of overall mortality with polymyxin-based therapy versus control antibiotics for treatment of
carbapenem-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae infections in controlled studies.
Variables Studies, no.
(patients, no.)
Comparison of mortality
between polymyxins and
control OR (95% CI); P
Heterogeneity of
studies included
Carbapenem-resistant K. pneumoniae 10 (414) 0.71 (0.48–1.05); p = 0.09 I2 = 0%; Q = 8.98; p = 0.53
Bloodstream infection 12 (551) 0.75 (0.52–1.08); p = 0.12 I2 = 0%; Q = 10.04; p = 0.53
By study design
Prospective 8 (345) 0.92 (0.55–1.54); p = 0.76 I2 = 0%; Q = 6.34; p = 0.50
Retrospective 12 (491) 0.70 (0.48–1.03); p = 0.07 I2 = 0%; Q = 9.81; p = 0.55
By concomitant antibiotics
Polymyxin alone 12 (133) 1.24 (0.80–1.93); p = 0.33 I2 = 0%; Q = 8.83; p = 0.64
Polymyxin + carbapenem 7 (35) 0.84 (0.33–2.13); p = 0.71 I2 = 0%; Q = 3.48; p = 0.72
Polymyxin + tigecycline 13 (118) 0.81 (0.50–1.33); p = 0.41 I2 = 12.50%; Q = 13.71; p = 0.32
Polymyxin + aminoglycoside 9 (78) 0.91 (0.50–1.63); p = 0.75 I2 = 5.63%; Q = 8.47; p = 0.38
Polymyxin + ≥2 antibiotics 11 (72) 0.51 (0.27–0.97); p = 0.04 I2 = 18.26%; Q = 12.23; p = 0.27
Abbreviations: OR, odds ratio; CI, conﬁdence interval.
Table 3 – Subgroup analysis of mortality with different polymyxin treatment strategies in the treatment of
carbapenem-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae infections.
Mortality Studies, no.
(patients, no.)
Comparison of mortality
between different treatment
strategies OR (95% CI); P
Heterogeneity of
studies included
By 28-day or 30-day
Monotherapy-Control 8 (303) 1.15 (0.66–2.01); P = 0.60 I2 = 0%; Q = 4.17; P = 0.76
Combination-Control 9 (410) 0.49 (0.31–0.75); P < 0.01 I2 = 0%; Q = 7.15; P = 0.52
Combination-Monotherapy 7 (221) 0.36 (0.19–0.68); P < 0.01 I2 = 0%; Q = 3.29; P = 0.77
By 14-day
Monotherapy-Control 2 (122) 0.84 (0.35–2.00); P = 0.69 I2 = 0%; Q = 0.08; P = 0.78
Combination-Control 2 (110) 0.76 (0.27–2.16); P = 0.60 I2 = 21.20%; Q = 1.27; P = 0.26
Combination-Monotherapy 2 (80) 0.91 (0.28–2.96); P = 0.88 I2 = 36.47%; Q = 1.57; P = 0.21
By In hospital
Combination-Control 3 (73) 2.01 (0.56–7.20); P = 0.28 I2 = 0%; Q = 0.71; P = 0.70
Combination-Monotherapy 2 (89) 0.97 (0.38–2.46); P = 0.95 I2 = 31.08%; Q = 1.45; P = 0.23
By All-cause
Combination-Control 2 (41) 3.00 (0.74–12.26); P = 0.125 I2 = 0%; Q = 0.02; P = 0.87
Abbreviations: OR, odds ratio; CI, conﬁdence interval.
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ig. 3 – A funnel plot of mortality rate in patients treated
ith polymyxins compared with that in patients treated
ith other antibiotics for infections caused by
arbapenemase-producing Enterobacteriaceae and
arbapenem-resistant Enterobacteriaceae.bacteria, have recently become the focus of interest to
clinicians.36 Nevertheless, before polymyxins were widely
reintroduced in the clinic, comprehensive and objective
evaluation of these “old antibiotics” was of great necessity.
In this systemic review, we assessed the available evi-
dence for the efﬁcacy of polymyxins in treating CRE infections.
Although no statistical difference was observed, a strong
tendency toward lower mortality was noted in the polymyxin-
treated groups (OR, 0.79; 95% CI, 0.58–1.08). As for the clinical
and microbiological response, pooled data showed no signif-
icant difference between the two groups. Therefore, we  can
at least conclude that polymyxins are as efﬁcacious as other
antibiotics for treating CRE infections.
Nevertheless, the rapid emergence of resistant isolates and
suboptimal pharmacokinetics may challenge the efﬁcacy of
polymyxins in treating MDR infections, especially bacteremia
and pneumonia.37,38 Many clinicians believe that combina-
tion therapy may overcome these shortcomings. Prospective
studies showed that polymyxin-based combination therapy
i s . 2 0
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could result in better clinical and microbiological outcomes
than monotherapy, but failed to provide evidence for the supe-
riority of combination therapy in lowering mortality when
treating MDR  Acinetobacter baumannii infections.39–41 The role
of combination therapy in CRE infections has not been well
evaluated. In the subgroup analyses of our study, polymyxin
monotherapy did not lower the 28-day or 30-day mortality,
and the outcome was in favor of the control groups. In con-
trast, combination therapy signiﬁcantly lowered the 28-day or
30-day mortality. This indicates that polymyxin combination
therapy may have an advantage over monotherapy in treating
CRE infections, although the evidence is not strong enough.
Several important questions regarding combination ther-
apy remain unanswered, such as the best combination for
each infection type, the continued role for carbapenems in
combination therapy, and the timing of combination ther-
apy initiation.7 A number of in vitro synergy tests have
been performed to verify the synergistic effects of polymyx-
ins in combination with other antibiotics.42–44 However, the
signiﬁcant synergy observed in vitro should be carefully inter-
preted, because the PK/PD effects of drugs in vivo, bacterial
load, and drug concentrations in speciﬁc sites of infec-
tion are different.45 A recent study found that when the
minimum inhibitory concentrations (MICs) for carbapenems
were ≤8 mg/L, carbapenem-containing regimens seemed to
offer therapeutic advantage over other regimens.46 However,
for Enterobacteriaceae with MICs for carbapenems >8 mg/L, a
combination of two or even three antibiotics, such as col-
istin, high-dose tigecycline, aminoglycoside, and fosfomycin,
seemed to decrease mortality.46 In this study, subgroup anal-
yses revealed that polymyxins combined with carbapenems,
tigecycline, or aminoglycosides could not signiﬁcantly lower
mortality; only triple polymyxin-containing combinations
seemed to do so. Considering the limited number of patients
and potential bias existing in the included studies, we cannot
draw deﬁnitive conclusions. Much  research is needed in the
future to address these signiﬁcant questions.
The biggest limitation to the wider clinical application
of polymyxins is the dosing-related nephrotoxicity and neu-
rotoxicity. Among the included studies, only one controlled
study and two single-arm studies evaluated the occurrence of
nephrotoxicity, and pooled analysis showed an incidence rate
of 19.2%. No studies have reported any incidences of neuro-
toxicity, such as seizures, encephalopathy, and neuromuscular
blockade. Owing to the limited available data, we were unable
to compare the safety between the polymyxin-treated groups
and the control groups. Recent studies report less frequent and
severe adverse effects than that reported in the 1970s.47 Other
published systemic reviews have concluded that the admin-
istration of polymyxins was not associated with a relatively
higher incidence of nephrotoxicity.36,41 Possible reasons might
be improved puriﬁed drug formulations, careful dosing, close
renal function monitoring, and more  advanced critical care
services.38 However, renal function should always be closely
monitored during administration, and the clinical safety of
polymyxins requires further investigation.Our study should be interpreted with caution, as it has lim-
itations that must be taken into account. The main limitation
is that none of the included studies were prospective ran-
domized controlled trials (RCTs). Therefore, we  were unable to 1 5;1  9(2):170–180
control for some confounding factors such as different patient
populations, different sites of infections, different genotypes
of pathogens, and different antimicrobial susceptibility break-
points. Another limitation is that most of the included studies
did not provide sufﬁcient detail to facilitate the comprehen-
sive interpretation of the results, such as the MICs, total daily
doses, time to initiate therapy, and duration of therapy. In
addition, the sample size for speciﬁc subgroup analysis was
small, which may reduce the power of statistical analyses.
In summary, this systematic review and meta-analysis
indicates that polymyxins and other antimicrobial thera-
pies may have similar efﬁcacy in the treatment of infections
caused by carbapenemase-producing Enterobacteriaceae and
CRE. Compared with polymyxin monotherapy, combination
regimens may achieve lower 28-day or 30-day mortality. How-
ever, the inherent limitations of the included studies prevent
us from reaching deﬁnitive conclusions. Future large-volume,
well-designed RCTs are required to determine the role of
polymyxins in treating CRE infections.
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